Fairvalue-Calculator Fairvalue-Calculator
EN DE

PT Hetzer Medical Indonesia Tbk (MEDS) Fair Value & Analysis

Healthcare · ID · Market cap 109B IDR

Price74.00 IDR
Fair Value139.10 IDR
Upside+88.0%
Quality95/100
Evidence: Low Range 104.32 IDR – 173.87 IDR

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

PT Hetzer Medical Indonesia Tbk (MEDS) currently trades at 74.00 IDR, while our model-based Fair Value estimate is 139.10 IDR — implying the stock looks roughly 88.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

PT Hetzer Medical Indonesia Tbk manufactures and sells 4D masks in Indonesia. It offers stethoscopes, bouffant caps, face masks, and tensiometer. The company was founded in 2010 and is based in Cimahi, Indonesia.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -60% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -38% Medline Inc (MDLN) -16% Becton, Dickinson and Company (BDX) -26% Alcon Inc (ALC) -32%

Frequently asked questions

Is PT Hetzer Medical Indonesia Tbk (MEDS) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 139.10 IDR versus a price of 74.00 IDR — about +88% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MEDS?
Our 21-model fair value for PT Hetzer Medical Indonesia Tbk is 139.10 IDR (as of Jun 24, 2026), built from audited fundamentals. The current price is 74.00 IDR.
What is the quality score of MEDS?
PT Hetzer Medical Indonesia Tbk has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.